Karyopharm Therapeutics Inc. has submitted a New Drug Application to FDA, seeking accelerated approval for Xpovio (selinexor), the company’s first-in-class, oral selective inhibitor of nuclear export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation, including CAR-T cell therapy.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
